For research use only. Not for therapeutic Use.
EBNA1-IN-SC7 (compound SC7) is a selective Epstein-Barr nuclear antigen 1 (EBNA1) inhibitor that interferes with EBNA1-DNA binding activity with an IC50 value of 23 μM. EBNA1-IN-SC7 is used in EBV (Epstein-Barr virus)-related cancer research[1].
EBNA1-IN-SC7 (compound SC7) (5 µM) can completely block transcriptional activation of EBNA1 and show a 60% inhibition of Zta (EBV-encoded b-zip DNA binding protein) trans-activation in HEK293T cells[2].
EBNA1-IN-SC7 (compound SC7) (10 µM, 6 days) has no significant effect on EBV genome copy number of Raji Burkitt lymphoma cells[2].
| Catalog Number | I042944 |
| CAS Number | 324022-08-4 |
| Synonyms | [4-[acetyl(naphthalen-2-ylsulfonyl)amino]-2-bromophenyl] acetate |
| Molecular Formula | C20H16BrNO5S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H16BrNO5S/c1-13(23)22(17-8-10-20(19(21)12-17)27-14(2)24)28(25,26)18-9-7-15-5-3-4-6-16(15)11-18/h3-12H,1-2H3 |
| InChIKey | SSARAOHVKXASDW-UHFFFAOYSA-N |
| SMILES | CC(=O)N(C1=CC(=C(C=C1)OC(=O)C)Br)S(=O)(=O)C2=CC3=CC=CC=C3C=C2 |
| Reference | [1]. Lijun Jiang, et al. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics. 2018 Oct 22;8(19):5307-5319. [2]. Ning Li, et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One. 2010 Apr 12;5(4):e10126. |
